Project Grant HT94252410661
Award Date 6/15/24
Completion Date 6/14/28
Dollars Obligated $1.6M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Sarasota, FL 34243, USA
Similar Awards
- The Defense Health Agency awarded a $489,997 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The Roskamp Institute, Inc. in Sarasota, Florida. The grant, awarded on September 1, 2024, will fund research to delineate the therapeutic effect of PTEN inhibition on mitigating chronic microglia activation and the chronic sequelae of repetitive mild traumatic brain injury (mTBI). The Roskamp Institute, a non-profit biotechnology research organization, has...
- The U.S. Defense Health Agency awarded a $817,200 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The Roskamp Institute, Inc. in Sarasota, Florida. The grant, awarded on September 1, 2024, will support a 3-year research project titled "Targeting APOE Bioenergetics for Reducing the Risk of Neurodegeneration After Chronic Traumatic Brain Injury." The research aims to investigate mitochondrial bioenergetics, tau protein pathology,...
- This federal Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $3,268,799.00 to The Roskamp Institute, Inc. to conduct research on the therapeutic effects of a novel blood-brain barrier-penetrable PPAR agonist compound for chronic outcomes following age-related repetitive mild traumatic brain injury. The award period spans from September 15, 2025 to September 14, 2029. The Roskamp Institute, a non-profit biotechnology...
- The Defense Health Agency awarded a $749,905 Project Grant to The Roskamp Institute Inc. under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research from September 2023 through September 2026 to investigate microglial NOX2/NLRP3 inflammasome activation and its role in driving tau pathology and cognitive impairments in chronic traumatic brain injury. Specifically, the Roskamp Institute will conduct basic, applied, and advanced biomedical...
- The Defense Health Agency awarded The Roskamp Institute, Inc. a $817,085 Project Grant under the Military Medical Research and Development program to conduct research on amnion cell secretome-mediated therapy for traumatic brain injury. The three-year award runs from June 1, 2023 to May 31, 2026 and will support The Roskamp Institute's investigation into potential therapies using amnion-derived cell treatments to address neuroinflammation and other vascular contributions to traumatic brain...
- This federal Project Grant award for $327,194 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to The Roskamp Institute, Inc., a biotechnology research organization based in Sarasota, Florida. The purpose of this 3-year award, with a performance period from September 1, 2024 to August 31, 2027, is to conduct research on delineating the therapeutic effect of PTEN inhibition for mitigating chronic microglia activation and the...
- The U.S. Defense Health Agency awarded a $817,027 Project Grant to The Roskamp Institute, Inc. in Sarasota, Florida under the Military Medical Research and Development program (CFDA 12.420). The 3-year grant, running from August 15, 2023 to August 14, 2026, will support the institute's research on an "amnion-derived multipotent cell secretome-medicated therapy for Gulf War Illness." The Roskamp Institute is a non-profit biotechnology research organization that has previously...
- The Defense Health Agency awarded a $1,973,398 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to Azevan Pharmaceuticals Inc. in Bethlehem, PA. The grant supports the development of a new drug to prevent the effects of mild traumatic brain injury (TBI) or concussion. The research project will be conducted over a 2-year period from June 2024 to June 2026. The goal is to advance the development of an innovative medical solution to address this critical...
- The Defense Health Agency awarded a $3.755 million Project Grant to the University of Wisconsin-Madison through the Military Medical Research and Development program (CFDA 12.420) to investigate dual orexin antagonist treatment to prevent neurobehavioral sequelae of traumatic brain injury from April 1, 2023 to March 31, 2027. The Military Medical Research and Development program supports innovative medical research to improve warfighter health and transform public healthcare. Under this award,...
- This $6,214,900 Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program supports research on the role of genetic risk factors and immune response on neurovascular unit (NVU) function in post-traumatic brain injury (TBI) cognitive impairment. The primary awardee, the Scintillon Institute, a non-profit biomedical research organization in San Diego, California, will conduct this advanced scientific investigation over...